Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of "Buy" by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $10.67.

AQST has been the topic of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Lake Street Capital dropped their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $2.45 on Tuesday. The company's fifty day moving average price is $2.75 and its 200-day moving average price is $3.32. The firm has a market capitalization of $243.35 million, a price-to-earnings ratio of -5.44 and a beta of 2.02. Aquestive Therapeutics has a one year low of $2.12 and a one year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. As a group, equities research analysts expect that Aquestive Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Summit Wealth & Retirement Planning Inc. bought a new position in shares of Aquestive Therapeutics in the 1st quarter worth approximately $29,000. Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics in the first quarter worth about $31,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of Aquestive Therapeutics during the first quarter valued at approximately $33,000. New York State Common Retirement Fund lifted its holdings in shares of Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Aquestive Therapeutics in the 4th quarter worth approximately $44,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.